| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:51 UTC |
|---|
| Update Date | 2022-03-07 02:51:55 UTC |
|---|
| HMDB ID | HMDB0015277 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Diphenylpyraline |
|---|
| Description | Diphenylpyraline, also known as difenilpiralina or lergobine, belongs to the class of organic compounds known as diphenylmethanes. Diphenylmethanes are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups. Diphenylpyraline (DPP; sold as Allergen, Arbid, Belfene, Diafen, Hispril, Histyn, Lergobine, Lyssipol, Mepiben, Neargal) is a first-generation antihistamine with anticholinergic effects of the diphenylpiperidine class. DPP has also been found to act as a dopamine reuptake inhibitor and produces hyperactivity in rodents. Diphenylpyraline is a drug which is used for use in the treatment of allergic rhinitis, hay fever, and allergic skin disorders. It has been shown to be useful in the treatment of Parkinsonism. Diphenylpyraline is a very strong basic compound (based on its pKa). In humans, diphenylpyraline is involved in diphenylpyraline h1-antihistamine action. Diphenylpyraline is a potentially toxic compound. It is marketed in Europe for the treatment of allergies. |
|---|
| Structure | CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1 InChI=1S/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3 |
|---|
| Synonyms | | Value | Source |
|---|
| 1-Methyl-4-hydroxypiperidine benzhydryl ether | ChEBI | | 1-Methyl-4-piperidyl benzhydryl ether | ChEBI | | 4-(Benzhydryloxy)-1-methylpiperidine | ChEBI | | 4-(Benzhydryloxy)-N-methylpiperidine | ChEBI | | Difenilpiralina | ChEBI | | Diphenylpyralamine | ChEBI | | Diphenylpyralinum | ChEBI | | Diphenylpyrilene | HMDB | | 4-Diphenylmethoxy-1-methylpiperidine | HMDB | | Diphenylpyraline maleate (2:1) | HMDB | | Diphenylpyraline hydrochloride | HMDB | | Lergobine | HMDB |
|
|---|
| Chemical Formula | C19H23NO |
|---|
| Average Molecular Weight | 281.392 |
|---|
| Monoisotopic Molecular Weight | 281.177964363 |
|---|
| IUPAC Name | 4-(diphenylmethoxy)-1-methylpiperidine |
|---|
| Traditional Name | diphenylpyraline |
|---|
| CAS Registry Number | 147-20-6 |
|---|
| SMILES | CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1 |
|---|
| InChI Identifier | InChI=1S/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3 |
|---|
| InChI Key | OWQUZNMMYNAXSL-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as diphenylmethanes. Diphenylmethanes are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Diphenylmethanes |
|---|
| Direct Parent | Diphenylmethanes |
|---|
| Alternative Parents | |
|---|
| Substituents | - Diphenylmethane
- Benzylether
- Piperidine
- Tertiary aliphatic amine
- Tertiary amine
- Azacycle
- Organoheterocyclic compound
- Ether
- Dialkyl ether
- Hydrocarbon derivative
- Amine
- Organooxygen compound
- Organonitrogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Organopnictogen compound
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Not Available | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.019 g/L | Not Available | | LogP | 3.7 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 6.65 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 12.2212 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.48 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 39.0 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1784.0 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 287.5 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 185.2 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 187.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 176.3 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 470.9 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 461.5 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 411.4 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1195.7 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 400.1 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1131.7 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 284.8 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 342.4 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 295.5 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 265.3 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatized |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental GC-MS | GC-MS Spectrum - Diphenylpyraline EI-B (Non-derivatized) | splash10-0002-9500000000-c0c4dde4b9a2e2daa726 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | | Experimental GC-MS | GC-MS Spectrum - Diphenylpyraline EI-B (Non-derivatized) | splash10-0002-9500000000-c0c4dde4b9a2e2daa726 | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Diphenylpyraline GC-MS (Non-derivatized) - 70eV, Positive | splash10-014i-9710000000-a770606b36046ca8a4ae | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Diphenylpyraline GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Diphenylpyraline 10V, Positive-QTOF | splash10-001i-2090000000-f121f756a940c93c3c82 | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Diphenylpyraline 20V, Positive-QTOF | splash10-00ls-6590000000-13f8de940c2071abfbe5 | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Diphenylpyraline 40V, Positive-QTOF | splash10-01b9-9200000000-9ffe64cee5b5f40c2ec1 | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Diphenylpyraline 10V, Negative-QTOF | splash10-001i-1190000000-602133655b9c8911993a | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Diphenylpyraline 20V, Negative-QTOF | splash10-001i-1490000000-3becf8ff3d41f41e70db | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Diphenylpyraline 40V, Negative-QTOF | splash10-0059-9600000000-8ed7a3e501298037b71b | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Diphenylpyraline 10V, Positive-QTOF | splash10-001i-0390000000-e5129a83970231fe41fe | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Diphenylpyraline 20V, Positive-QTOF | splash10-014i-0910000000-798a31f1be1c1e43f403 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Diphenylpyraline 40V, Positive-QTOF | splash10-0002-9300000000-a4f815502c5ef2b7c10f | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Diphenylpyraline 10V, Negative-QTOF | splash10-001i-0090000000-a2d4cba31dc9278eeca1 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Diphenylpyraline 20V, Negative-QTOF | splash10-001i-0890000000-33c92852c81f3c229784 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Diphenylpyraline 40V, Negative-QTOF | splash10-0a4i-2910000000-3458648a46e7b108c7af | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Lapa GB, Mathews TA, Harp J, Budygin EA, Jones SR: Diphenylpyraline, a histamine H1 receptor antagonist, has psychostimulant properties. Eur J Pharmacol. 2005 Jan 4;506(3):237-40. Epub 2004 Dec 8. [PubMed:15627433 ]
- Puhakka H, Rantanen T, Virolainen E: Diphenylpyraline (Lergobine) in the treatment of patients suffering from allergic and vasomotor rhinitis. J Int Med Res. 1977;5(1):37-41. [PubMed:14039 ]
- Ohno T, Kobayashi S, Hayashi M, Sakurai M, Kanazawa I: Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients. J Neurol Sci. 2001 Jan 1;182(2):95-7. [PubMed:11137513 ]
|
|---|